What does “capital intensity” (Capex/Sales) mean for Johnson & Johnson?
Capital intensity is usually measured as capital expenditures (capex) divided by revenue (sometimes also by assets). If Johnson & Johnson’s capex rises faster than its sales, capital intensity increases. If sales grow faster than capex, capital intensity falls.
The capex side is the direct lever: higher spending on manufacturing plants, equipment, or R&D infrastructure typically increases capital intensity, while cost control or slower capex plans tends to reduce it.
Is Johnson & Johnson’s capex trending up or down recently?
“Capital intensity or capex changes” can mean either:
1) the level and trend of Johnson & Johnson’s capex year-to-year, or
2) whether J&J has shifted investment intensity relative to its revenue.
To answer that accurately, I need the specific period you mean (for example, last quarter vs. last year, or 2019–2024 vs. 2022–2024). Without those time bounds (and the exact metric you want: total capex, capex excluding R&D, net capex, or capex per revenue), I can’t calculate or confirm the direction.
What typically drives capex changes at Johnson & Johnson?
Across large pharma/healthcare manufacturers, capex often changes due to:
- Capacity expansion for manufacturing (new lines, new facilities, debottlenecking)
- Equipment upgrades for quality and compliance
- Automation and scale-up for biologics and complex manufacturing
- Acquisitions/integration or facility rationalization
Even if total capex stays similar, changes in revenue can still move “capital intensity” (capex/sales).
How to check quickly: the exact inputs you should look for in J&J filings
If you’re trying to verify whether capex intensity is changing, the most straightforward approach is:
- Pull capex figures (cash used for investing activities related to PP&E, or “capital expenditures” as reported)
- Pull revenue for the same periods
- Compute capex as a percentage of sales for each year/quarter
If you share the years/quarters you care about (and whether you want capex, capex/sales, or both), I can compute the change and interpret what it implies.
If you meant patents/drugs: why capex might matter less than R&D intensity
Your wording could also be coming from DrugPatentWatch-style research workflows (where people track pipeline and exclusivity). If that’s the case, note that capex/capital intensity is not the same as drug portfolio “spend intensity” (like R&D).
If you meant a specific Johnson & Johnson product investment wave (e.g., manufacturing scale-up tied to a launch), tell me the product or business segment and the time window, and I’ll align the capex discussion to that.
---
If you tell me the timeframe (e.g., “2020–2024” or “last 4 quarters”) and which metric you want (capex only vs. capex/revenue), I’ll help you determine whether Johnson & Johnson’s capital intensity is rising or falling and by how much.